Toujeo LA is a Recombinant Protein owned by Sanofi, and is involved in 34 clinical trials, of which 31 were completed, and 3 are ongoing.

Insulin glargine is a recombinant human insulin analog that binds to insulin receptor (IR) in the regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake especially by skeletal muscle and fat mediated through the facilitative glucose transporter Glut4. Insulin inhibits hepatic glucose production, lipolysis in the adipocyte, inhibits proteolysis, and enhances protein synthesis.

The revenue for Toujeo LA is expected to reach a total of $21.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Toujeo LA NPV Report.

Toujeo LA is currently owned by Sanofi.

Toujeo LA Overview

Insulin glargine recombinant (Toujeo / Lantus XR/ Toujeo Solostar/ Toujeo Max Solostar/ Toujeo Max) is a long acting human insulin analogue acts as anti-diabetic preparation. It is formulated as a injection for the subcutaneous route of administration. It is indicated to improve glycemic control in adults with diabetes mellitus. It is under development for the treatment for type 1 diabetes and type 2 diabetes.

Sanofi Overview

Sanofi is a healthcare company, which is engaged in the discovery, development, manufacturing and marketing of a wide range of medicines and vaccines. Its portfolio includes medicines for the treatment of cancer, diabetes, rare diseases, multiple sclerosis and cardiovascular diseases; human vaccines for protection against various bacterial and viral diseases; and other products. The company also offers consumer healthcare products for digestion; allergy; cough, cold, flu and sinus; pain; women’s health; and vitamins, minerals and supplements. Sanofi‘s R&D efforts focus on advancing a combination drugs to increase the effectiveness of treatments and on advancing the formulation of new biologics to produce precision medicines. It has operations in Europe, the Americas, Asia-Pacific, Africa and the Middle East. Sanofi is headquartered in Paris, France.

The company reported revenues of (Euro) EUR39,175 million for the fiscal year ended December 2021 (FY2021), an increase of 4.8% over FY2020. In FY2021, the company’s operating margin was 20.7%, compared to an operating margin of 37.8% in FY2020. In FY2021, the company recorded a net margin of 15.9%, compared to a net margin of 32.9% in FY2020. The company reported revenues of EUR13,138 million for the third quarter ended September 2022, a decrease of 36.8% over the previous quarter.

Quick View – Toujeo LA

Report Segments
  • Innovator (NME)
Drug Name
  • Toujeo LA
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.